PVCT Provectus Biopharmaceuticals - Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4319 of 5506  at  7/11/2019 11:21:57 AM  by

Hombre77

The following message was updated on 7/11/2019 11:23:47 AM.

 In response to msg 4318 by  PVCTismyBMW
view thread

Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types

  
I agree with everything you wrote. Which is why I'm lukewarm to LTG's comment about PVCT being acquired prior to an FDA approval -  I just don't see how a decent valuation could realistically be achieved in such a scenario.
 
Perhaps I'm being somewhat naive, but I don't see that Provectus has a lot of bargaining power with BP at the moment, so any type of financing / trial partnership is likely to come at a high price -  e.g. conceding significant future rights to the sponsoring company. 
 
I'm very aware that this is an unusual situation, but it's the current reality so in the absence of a miracle, I don't see any prospect of a near-term buyout at an acceptable price (absent an FDA approval).  The only way I can see a buyout prior to FDA approval is if it includes Contingent Value Rights (a CVR - see link below) that would allow current shareholders to participate in future upside.
 
I would love to be wrong, so if anybody has ideas for an alternative path forward that could bring the share price to a level that would ultimately facilitate an acquisition at a price exceeding $1.00, I'd be very interested in hearing about it. 
 
 
 
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 228
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...